How many insider trades does FilingIQ track for GNTA?

FilingIQ tracks 6 Form 4 insider transactions for GNTA (Genenta Science S.p.A.), covering filings from Mar 30, 2026 onwards. 6 of those were filed in the last 90 days.

Are GNTA insiders net buyers or net sellers?

Across the full Form 4 history for GNTA, 0 transactions (0%) were open-market purchases and 0 (0%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.

Where does GNTA insider data come from?

Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.

What sector is GNTA in?

Genenta Science S.p.A. (GNTA) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $16.33M.

GNTA insider trading

NasdaqCM Healthcare

Genenta Science S.p.A. — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.

Total Form 4 trades

Last 90 days

Buys / sells

0% / 0%

Market cap

$16.33M

About Genenta Science S.p.A.

Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. Its lead product candidate is Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter. The company is developing Temferon for use in the treatment of other solid tumor indications, locally advanced hepatocellular carcinoma, and intra-hepatic cholangiocarcinoma. In addition, it develops biologic platform to deliver immunomodulatory molecules directly to the tumor by infiltrating monocytes/macrophages. The company was incorporated in 2014 and is headquartered in Milan, Italy.

Company website: www.genenta.com

GNTA insider activity at a glance

FilingIQ has scored 6 insider transactions for GNTA since Mar 30, 2026. The most recent filing in our index is dated Mar 30, 2026.

Across the full history, 0 open-market purchases and 0 open-market sales were filed under transaction codes P and S respectively. Compensatory share awards (code A) and option exercises (code M) are tracked separately and not counted here.

View live GNTA trades on FilingIQ Raw filings on SEC EDGAR

Other Healthcare tickers with recent insider activity

UTHR 1,098

UNITED THERAPEUTICS Corp

APLS 279

Apellis Pharmaceuticals, Inc.

KMDA 218

KAMADA LTD

BMY 185

BRISTOL MYERS SQUIBB CO

ADPT 184

Adaptive Biotechnologies Corp

GH 169

Guardant Health, Inc.

ISRG 166

INTUITIVE SURGICAL INC

VTRS 165

Viatris Inc

Frequently asked

How many insider trades does FilingIQ track for GNTA?: FilingIQ tracks 6 Form 4 insider transactions for GNTA (Genenta Science S.p.A.), covering filings from Mar 30, 2026 onwards. 6 of those were filed in the last 90 days.
Are GNTA insiders net buyers or net sellers?: Across the full Form 4 history for GNTA, 0 transactions (0%) were open-market purchases and 0 (0%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
Where does GNTA insider data come from?: Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
What sector is GNTA in?: Genenta Science S.p.A. (GNTA) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $16.33M.

Methodology & sources

Every GNTA insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.